India Glycols' Three-Way Split: Demerger Listing Roadmap
Effective date fixed for Sept 1 — two new listed entities as pharmacy and spirits businesses separate from the parent. Here is the structure, timelines, and what shareholders should expect.
India Glycols Ltd
BSE 500201 | Chemicals
Diversified
Glycols, pharma, spirits
₹10,300 Cr
Full year, consolidated
₹4,600 Cr
As of Aug 20, 2026
59.6%
As of Jun 30, 2026
Sept 1, 2026
Scheme effective date
Regulatory approval complete; listings begin next week
India Glycols fixes effective date for three-way split
India Glycols announced today that the National Company Law Tribunal (NCLT) order approving the Scheme of Arrangement will become effective on September 1, 2026. The Record Date — when shareholder entitlements are locked — is September 2, 2026. Both resulting companies, Ennature Bio Pharma Limited (EBL) and IG L Spirits Limited (IGSL), are planned for listing on NSE and BSE.
Read:This is a hard date that settles the demerger timeline. Shareholders now have visibility into exactly when they will hold three separate entities: India Glycols (glycols parent + residual), Ennature Bio Pharma (pharma), and IG L Spirits (spirits division). The compressed timeline — just 11 days from today — gives the stock exchange and registrar minimal runway but high certainty.
BSE Filing, Aug 21, 2026NCLT approves scheme of arrangement
India Glycols received the certified order from the National Company Law Tribunal (NCLT), Allahabad Bench, approving the Scheme of Arrangement under Sections 230–232 of the Companies Act, 2013. The order, dated July 17, 2026, sanctioned the demerger of India Glycols into Ennature Bio Pharma Limited and IG L Spirits Limited, with an Appointed Date of April 1, 2026 (effective retroactively for accounting purposes).
Read:NCLT approval is the final regulatory hurdle. With this certified order in hand, India Glycols can now move to Effective Date (when it files with the Registrar of Companies) and Record Date (when share entitlements are crystallized). The Appointed Date of April 1 means the demerged entities' financials are consolidated from that date.
NCLT Order, Allahabad Bench, Jul 17, 2026The demerger separates India Glycols into three publicly listed entities. For shareholders, this crystallizes a strategic pivot the company has been building for a decade — unlocking the value of pharma and spirits businesses that, while grown organically within India Glycols, now trade on distinct industrial and commercial profiles. The NCLT-approved scheme has been rubber-stamped by the board; the final steps are mechanical.
Share swap ratios and post-demerger ownership
- 1
Record Date
September 2, 2026 — The last day to own India Glycols shares to receive allotments in EBL and IGSL. Shares will be held in three separate accounts.
- 2
Demerged Entity 1: Ennature Bio Pharma (EBL)
Receives India Glycols' pharmaceutical division. Shareholders get 1 EBL share for every 3 INDGLY shares held. Face value: ₹5 per share. Listing planned on NSE and BSE.
- 3
Demerged Entity 2: IG L Spirits (IGSL)
Receives India Glycols' spirits and alcoholic beverages division. Shareholders get 1 IGSL share for every 1 INDGLY share held (1:1 ratio). Face value: ₹5 per share. Listing planned on NSE and BSE.
- 4
Residual: India Glycols (INDGLY)
Retains the glycols business, industrial alcohols, and specialty chemicals. Continues trading on BSE/NSE under its existing code.
- 5
Listing Timeline
EBL and IGSL are expected to begin trading in early September 2026, subject to final regulatory clearance from the stock exchanges.
The entitlement ratios mean a shareholder with 100 INDGLY shares will receive 33 EBL shares (100 ÷ 3) and 100 IGSL shares at the Record Date. The residual India Glycols shares remain with the shareholder; the company's name and ticker do not change.
Three focused businesses, three distinct investor bases
India Glycols has historically been a single conglomerate trading at a blended valuation — a chemical company with pharma and spirits subsidiaries. The market has struggled to value each division separately; each attracts different investor types (cyclical chemical buyers vs. pharma growth buyers vs. beverages traders) but all are wrapped into one ticker.
The demerger unlocks this conglomerate discount. Institutional pharma investors can now buy EBL on its pharma-sector metrics (growth, margin, competitive position) without assuming glycol commodity risk. Spirits investors get a pure-play IGSL without chemical exposure. Cyclical chemical traders keep INDGLY as a focused glycols play. Individually, each should trade on its own fundamentals and peer multiples — likely at a higher aggregate valuation than the single combined entity.
The timing also matters: India's pharma sector (APIs and finished drugs) is in structural growth mode as cost-competitive manufacturing relocates from China. Spirits demand remains buoyant in India's consuming classes. Glycols have commodity cyclicality but are essential to polyesters, antifreeze, and industrial processes. Separating them now — while each has distinct tailwinds — maximizes the value capture for long-term holders.
Critical dates from approval to trading
Appointed Date — Demerged entities' accounting commences (retroactive). Financials are split from this date.
NCLT Order Date — National Company Law Tribunal approves the scheme.
Certified NCLT Order Received — India Glycols gets the final signed order from NCLT.
Effective Date — NCLT order is filed with the Registrar of Companies. Scheme becomes legally effective.
Record Date — Shareholder register is frozen. Entitlements (1 EBL per 3 INDGLY; 1 IGSL per 1 INDGLY) are determined.
Expected Trading Commencement — EBL and IGSL shares credit to demat accounts; trading begins on NSE and BSE (subject to exchange approvals).
Post-listing visibility
ebl-listing-price
Ennature Bio Pharma (EBL) listing price — will determine the market's initial pharma-sector valuation for the division. Watch for any subscription data or pre-listing trading indications.
igsl-listing-price
IG L Spirits (IGSL) listing price — spirits businesses in India trade at significant premiums due to growth and margin profiles. Initial pricing will reveal investor appetite for a pure-play spirits play.
indgly-residual-reaction
India Glycols stock reaction post-demerger — will the market reward the focus of a pure glycols/industrial chemicals company, or will it face selling pressure from holders who wanted pharma/spirits exposure?
corporate-governance
Separate board appointments, dividend policies, and capital allocation strategies for each entity — independent management will shape long-term returns.
integration-risks
Post-demerger separation risks: shared infrastructure, supplier relationships, customer contracts, and working capital management. Early earnings surprises (positive or negative) will indicate execution quality.
India Glycols' three-way split is now set to commence in just 11 days. The NCLT approval is signed, the effective date is fixed, and the shareholder entitlements are clear. For long-term holders of India Glycols, the demerger is a value-unlock event — three businesses with distinct growth profiles, risk profiles, and investor bases are now getting separate runway. The market will immediately price each on its own merits. Holders should expect volatility in the first weeks of trading as the three entities find their natural multiples; the focus over months ahead should be on each company's operational performance and capital discipline, not the listing-day euphoria or pessimism.
Informational and educational content only. Not investment advice.